Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and Their ratios between high- and low-affinity rolipram binding

Hsin Te Hsu, Wen Hung Wang, Cheng Ying Han, Chun Nan Chen, Chi Ming Chen, Wun-Chang Ko

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The phosphodiesterase (PDE)4 molecule exists as two distinct conformers, PDE4H and PDE4L, which have high and low affinities, respectively, for the selective PDE4 inhibitor, rolipram. The inhibition of PDE4H and PDE4L is associated with adverse responses, such as nausea, vomiting, and gastric hypersecretion, and with anti-inflammatory and bronchodilator effects, respectively. We determined the therapeutic (PDE4H/PDE4L) ratios of hesperetin-7-O-methylether, hesperetin-5,7,3′-O-trimethylether (HTME), hesperetin-7-O-acetate, hesperetin-7,3′-O-diacetate, hesperetin-5,7,3′-O-triacetate (HTA), hesperetin-5,7,3′-O-tripropionate, hesperetin-5,7,3′-O-tributyrate, hesperetin-5,7,3′-O-triisobutyrate, and hesperetin-5,7,3′-O-tripivatate, and compared these ratios to those of hesperetin, hesperetin-7,3′-O-dimethylether, hesperidin, and hesperidin-3′-O-methylether to identify derivatives with therapeutic ratios and to characterize the structure-activity relationships among these compounds. The activities of PDE isozymes 1 through 5 were measured using a two-step procedure using [3H]adenosine 3′,5′-cyclic monophosphate or [3H]guanosine 3′,5′-cyclic monophosphate as substrates. The inhibitory concentration (IC50) for 50% of PDE4 inhibition and effective concentration (EC50) for replacing 50% of [3H]rolipram binding on high-affinity rolipram-binding sites was taken as the PDE4L and PDE4H value, respectively. The HTME and the HTA dually inhibited PDE3 and PDE4, and displayed PDE4H/PDE4L ratios of 18.3 and 20.8, respectively, suggesting that they may be candidate drugs for treating asthma and chronic obstructive pulmonary disease (COPD) because the combined inhibition of PDE3 and PDE4 has synergistically anti-inflammatory and bronchodilator effects in COPD patients.

Original languageEnglish
Pages (from-to)2120-2127
Number of pages8
JournalJournal of Pharmaceutical Sciences
Volume102
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Rolipram
Phosphoric Diester Hydrolases
Guinea Pigs
Hesperidin
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Inhibitory Concentration 50
hesperetin
Anti-Inflammatory Agents
Type 4 Cyclic Nucleotide Phosphodiesterase
Phosphodiesterase 4 Inhibitors
Guanosine
Structure-Activity Relationship
Adenosine
Nausea
Isoenzymes
Vomiting

Keywords

  • 3′-O-triacetate
  • 3′-O-trimethylether
  • 7
  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Enzymes
  • Hesperetin-5
  • In vitro model
  • Inhibition
  • Phosphodiesterase (PDE)3/4 inhibition
  • Pulmonary
  • Structure activity relationship (SAR)

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and Their ratios between high- and low-affinity rolipram binding. / Hsu, Hsin Te; Wang, Wen Hung; Han, Cheng Ying; Chen, Chun Nan; Chen, Chi Ming; Ko, Wun-Chang.

In: Journal of Pharmaceutical Sciences, Vol. 102, No. 7, 07.2013, p. 2120-2127.

Research output: Contribution to journalArticle

Hsu, Hsin Te ; Wang, Wen Hung ; Han, Cheng Ying ; Chen, Chun Nan ; Chen, Chi Ming ; Ko, Wun-Chang. / Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and Their ratios between high- and low-affinity rolipram binding. In: Journal of Pharmaceutical Sciences. 2013 ; Vol. 102, No. 7. pp. 2120-2127.
@article{4aafc371547c4e06965493ad5ff7c312,
title = "Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and Their ratios between high- and low-affinity rolipram binding",
abstract = "The phosphodiesterase (PDE)4 molecule exists as two distinct conformers, PDE4H and PDE4L, which have high and low affinities, respectively, for the selective PDE4 inhibitor, rolipram. The inhibition of PDE4H and PDE4L is associated with adverse responses, such as nausea, vomiting, and gastric hypersecretion, and with anti-inflammatory and bronchodilator effects, respectively. We determined the therapeutic (PDE4H/PDE4L) ratios of hesperetin-7-O-methylether, hesperetin-5,7,3′-O-trimethylether (HTME), hesperetin-7-O-acetate, hesperetin-7,3′-O-diacetate, hesperetin-5,7,3′-O-triacetate (HTA), hesperetin-5,7,3′-O-tripropionate, hesperetin-5,7,3′-O-tributyrate, hesperetin-5,7,3′-O-triisobutyrate, and hesperetin-5,7,3′-O-tripivatate, and compared these ratios to those of hesperetin, hesperetin-7,3′-O-dimethylether, hesperidin, and hesperidin-3′-O-methylether to identify derivatives with therapeutic ratios and to characterize the structure-activity relationships among these compounds. The activities of PDE isozymes 1 through 5 were measured using a two-step procedure using [3H]adenosine 3′,5′-cyclic monophosphate or [3H]guanosine 3′,5′-cyclic monophosphate as substrates. The inhibitory concentration (IC50) for 50{\%} of PDE4 inhibition and effective concentration (EC50) for replacing 50{\%} of [3H]rolipram binding on high-affinity rolipram-binding sites was taken as the PDE4L and PDE4H value, respectively. The HTME and the HTA dually inhibited PDE3 and PDE4, and displayed PDE4H/PDE4L ratios of 18.3 and 20.8, respectively, suggesting that they may be candidate drugs for treating asthma and chronic obstructive pulmonary disease (COPD) because the combined inhibition of PDE3 and PDE4 has synergistically anti-inflammatory and bronchodilator effects in COPD patients.",
keywords = "3′-O-triacetate, 3′-O-trimethylether, 7, Asthma, Chronic obstructive pulmonary disease (COPD), Enzymes, Hesperetin-5, In vitro model, Inhibition, Phosphodiesterase (PDE)3/4 inhibition, Pulmonary, Structure activity relationship (SAR)",
author = "Hsu, {Hsin Te} and Wang, {Wen Hung} and Han, {Cheng Ying} and Chen, {Chun Nan} and Chen, {Chi Ming} and Wun-Chang Ko",
year = "2013",
month = "7",
doi = "10.1002/jps.23591",
language = "English",
volume = "102",
pages = "2120--2127",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and Their ratios between high- and low-affinity rolipram binding

AU - Hsu, Hsin Te

AU - Wang, Wen Hung

AU - Han, Cheng Ying

AU - Chen, Chun Nan

AU - Chen, Chi Ming

AU - Ko, Wun-Chang

PY - 2013/7

Y1 - 2013/7

N2 - The phosphodiesterase (PDE)4 molecule exists as two distinct conformers, PDE4H and PDE4L, which have high and low affinities, respectively, for the selective PDE4 inhibitor, rolipram. The inhibition of PDE4H and PDE4L is associated with adverse responses, such as nausea, vomiting, and gastric hypersecretion, and with anti-inflammatory and bronchodilator effects, respectively. We determined the therapeutic (PDE4H/PDE4L) ratios of hesperetin-7-O-methylether, hesperetin-5,7,3′-O-trimethylether (HTME), hesperetin-7-O-acetate, hesperetin-7,3′-O-diacetate, hesperetin-5,7,3′-O-triacetate (HTA), hesperetin-5,7,3′-O-tripropionate, hesperetin-5,7,3′-O-tributyrate, hesperetin-5,7,3′-O-triisobutyrate, and hesperetin-5,7,3′-O-tripivatate, and compared these ratios to those of hesperetin, hesperetin-7,3′-O-dimethylether, hesperidin, and hesperidin-3′-O-methylether to identify derivatives with therapeutic ratios and to characterize the structure-activity relationships among these compounds. The activities of PDE isozymes 1 through 5 were measured using a two-step procedure using [3H]adenosine 3′,5′-cyclic monophosphate or [3H]guanosine 3′,5′-cyclic monophosphate as substrates. The inhibitory concentration (IC50) for 50% of PDE4 inhibition and effective concentration (EC50) for replacing 50% of [3H]rolipram binding on high-affinity rolipram-binding sites was taken as the PDE4L and PDE4H value, respectively. The HTME and the HTA dually inhibited PDE3 and PDE4, and displayed PDE4H/PDE4L ratios of 18.3 and 20.8, respectively, suggesting that they may be candidate drugs for treating asthma and chronic obstructive pulmonary disease (COPD) because the combined inhibition of PDE3 and PDE4 has synergistically anti-inflammatory and bronchodilator effects in COPD patients.

AB - The phosphodiesterase (PDE)4 molecule exists as two distinct conformers, PDE4H and PDE4L, which have high and low affinities, respectively, for the selective PDE4 inhibitor, rolipram. The inhibition of PDE4H and PDE4L is associated with adverse responses, such as nausea, vomiting, and gastric hypersecretion, and with anti-inflammatory and bronchodilator effects, respectively. We determined the therapeutic (PDE4H/PDE4L) ratios of hesperetin-7-O-methylether, hesperetin-5,7,3′-O-trimethylether (HTME), hesperetin-7-O-acetate, hesperetin-7,3′-O-diacetate, hesperetin-5,7,3′-O-triacetate (HTA), hesperetin-5,7,3′-O-tripropionate, hesperetin-5,7,3′-O-tributyrate, hesperetin-5,7,3′-O-triisobutyrate, and hesperetin-5,7,3′-O-tripivatate, and compared these ratios to those of hesperetin, hesperetin-7,3′-O-dimethylether, hesperidin, and hesperidin-3′-O-methylether to identify derivatives with therapeutic ratios and to characterize the structure-activity relationships among these compounds. The activities of PDE isozymes 1 through 5 were measured using a two-step procedure using [3H]adenosine 3′,5′-cyclic monophosphate or [3H]guanosine 3′,5′-cyclic monophosphate as substrates. The inhibitory concentration (IC50) for 50% of PDE4 inhibition and effective concentration (EC50) for replacing 50% of [3H]rolipram binding on high-affinity rolipram-binding sites was taken as the PDE4L and PDE4H value, respectively. The HTME and the HTA dually inhibited PDE3 and PDE4, and displayed PDE4H/PDE4L ratios of 18.3 and 20.8, respectively, suggesting that they may be candidate drugs for treating asthma and chronic obstructive pulmonary disease (COPD) because the combined inhibition of PDE3 and PDE4 has synergistically anti-inflammatory and bronchodilator effects in COPD patients.

KW - 3′-O-triacetate

KW - 3′-O-trimethylether

KW - 7

KW - Asthma

KW - Chronic obstructive pulmonary disease (COPD)

KW - Enzymes

KW - Hesperetin-5

KW - In vitro model

KW - Inhibition

KW - Phosphodiesterase (PDE)3/4 inhibition

KW - Pulmonary

KW - Structure activity relationship (SAR)

UR - http://www.scopus.com/inward/record.url?scp=84879028731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879028731&partnerID=8YFLogxK

U2 - 10.1002/jps.23591

DO - 10.1002/jps.23591

M3 - Article

VL - 102

SP - 2120

EP - 2127

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 7

ER -